TP53 and acute myeloid leukemia: As additional myeloid specific therapies are showing robust response rates in MDS/AML patients (e.g., pevonedistat and sabatolimab), understanding how the TP53 mutant subgroup responds is of critical importance given clear differential outcomes in this patient subgroup.